Ureteral strictures and fistulae following radical hysterectomy. 1984

K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin

Three hundred patients have undergone radical hysterectomy and pelvic node dissection at The University of Alabama in Birmingham (UAB). Uretero-vaginal fistulae occurred in four (1.3%). None of these were associated with recurrent carcinoma. Two occurred because of intraoperative trauma and two were unexplained. Ureteral strictures occurred in 13 (4.3%). Three were early (within 3 months) and were due to benign causes. Ten were late (after 3 months) and were due to recurrent cancer. Thirty-two patients received whole pelvis radiation therapy for positive pelvic nodes or positive margins. None of these developed uretero-vaginal fistulae. Two developed ureteral obstruction and recurrent cancer was the etiology. Four patients received postoperative vaginal ovoids for positive vaginal margins. None developed a fistulae, but two developed ureteral obstruction secondary to recurrent cancer. Two patients received both whole pelvis and vaginal ovoid irradiation. No fistulae occurred, but one developed ureteral obstruction from recurrent cancer. Recurrent cancer causing ureteral obstruction was a serious finding as only 2 of 10 patients have been salvaged.

UI MeSH Term Description Entries
D007044 Hysterectomy Excision of the uterus. Hysterectomies
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005833 Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). Gynecologic Neoplasms,Female Genital Neoplasms,Neoplasms, Female Genital,Neoplasms, Gynecologic,Female Genital Neoplasm,Genital Neoplasm, Female,Gynecologic Neoplasm,Neoplasm, Female Genital,Neoplasm, Gynecologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
October 1984, AJR. American journal of roentgenology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
July 1966, Obstetrics and gynecology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
January 1983, Obstetrics and gynecology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
December 2011, Taiwanese journal of obstetrics & gynecology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
May 1967, International surgery,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
March 1981, The Journal of urology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
April 1987, Obstetrics and gynecology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
January 1993, Scandinavian journal of urology and nephrology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
April 2008, The Journal of urology,
K D Hatch, and G Parham, and H M Shingleton, and J W Orr, and J M Austin
August 2007, The Journal of urology,
Copied contents to your clipboard!